Allarity Therapeutics, Inc. (ALLR) - 8-K Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on October 12, 2022. The Company is an emerging growth company with its principal executive offices in Cambridge, MA. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "ALLR".
Key Financial Metrics
The filing references the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2022, to highlight a specific financial metric triggering the report.
- Stockholders' Equity: Approximately $8.0 million as of June 30, 2022.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide clear values for these metrics.
Material Changes and Listing Status
The Company received a notice from Nasdaq stating it failed to satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market. This rule requires a minimum stockholders' equity of $10.0 million. The Company's reported equity of $8.0 million fell below this threshold.
The notice has no immediate effect on the listing or trading of the Company's common stock.
Outlook, Management Commentary, and Risks
Compliance Timeline:
- Plan Submission: The Company has 45 calendar days (until November 26, 2022) to submit a plan to regain compliance.
- Compliance Period: If the plan is accepted, Nasdaq may grant up to 180 calendar days (until April 10, 2023) to evidence compliance.
- Appeal Rights: If the plan is rejected, the Company may appeal to a Nasdaq Hearings Panel.
Management Strategy: The Company is evaluating alternative courses of action to regain compliance and intends to submit a plan by the November 26, 2022 deadline. Additionally, the Company is considering transferring to the Nasdaq Capital Market, subject to satisfying those specific listing requirements.
Risks: There is no assurance that the Company will be able to regain compliance with the minimum stockholders' equity requirement or maintain compliance with other listing requirements.
Investor Verification Checklist
- Verify the Company's stockholders' equity as of the most recent reporting period to confirm the deficit.
- Monitor the submission of the compliance plan to Nasdaq by November 26, 2022.
- Review the Company's Form 10-Q for the period ended June 30, 2022, for detailed financial statements.
- Assess the feasibility of transferring to the Nasdaq Capital Market if Global Market compliance is not achieved.